Urinary metabolites of the new progestagen STS 557 (17 alpha-cyanomethyl-17-hydroxy-4,9-estradien-3-one) in the dog and rat.
Urinary metabolites of the new progestagen STS 557 (17 alpha-cyanomethyl-17-hydroxy-4,9-estradien-3-one) were isolated and characterized following oral administration of the 14 alpha, 15 alpha-tritium labelled compound to dogs and rats. 17 alpha-Cyanomethyl-11 beta, 17-dihydroxy-4,9-estradien-3-one (11 beta-OH-STS 557) and 17 alpha-cyanomethyl-1,3,5(10),9(11)-estratetraene-3,17-diol were identified by comparison with synthesized reference compounds. Mass spectra data indicate the following other pathways of STS 557 biotransformation: Hydroxylation in other positions than 11; hydrogenation; hydroxylation + hydrogenation; alteration of the 17 alpha-side chain.
D000284:Administration, Oral; D000818:Animals; D002855:Chromatography, Thin Layer; D004285:Dogs; D005260:Female; D007700:Kinetics; D008297:Male; D013058:Mass Spectrometry; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000652:urine; D045167:Progesterone Congeners / Q000652:urine*; D051381:Rats; D011919:Rats, Inbred Strains; D013045:Species Specificity; D013056:Spectrophotometry, Ultraviolet
D045167:Progesterone Congeners; C023635:dienogest; D009277:Nandrolone